Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Immune Responses To Antigen-Bearing Dendritic Cells in Patients With Malignancy

Phase 1

Completed

Conditions: Melanoma

Interventions: Biological: dendritic cell vaccine

First Posted Date: 2008-06-18

Last Posted Date: 2011-04-20

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 43

Registration Number: NCT00700167

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Vaccination of Prostate Cancer Patients With MUC-2-KLH Conjugate Plus the Immunological Adjuvant QS21

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Biological: MUC-2-KLH

First Posted Date: 2008-06-17

Last Posted Date: 2012-01-31

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 15

Registration Number: NCT00698711

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Vaccination of AJCC Stage IIB, IIC, III and IV Melanoma Patients With Human and Mouse Tyrosinase DNA Vaccines

Phase 1

Completed

Conditions: Melanoma
Skin

Interventions: Biological: human tyrosinase
Biological: mouse tyrosinase

First Posted Date: 2008-06-16

Last Posted Date: 2011-09-16

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 18

Registration Number: NCT00698100

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Dose-Seeking Trial of PCK3145 in Asymptomatic, Castrate Metastatic Prostate Cancer Patients.

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: PCK3145

First Posted Date: 2008-06-12

Last Posted Date: 2009-03-30

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 36

Registration Number: NCT00695851

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Intravenous Oxaliplatin Plus Irinotecan in Patients With Unresectable Hepatic Metastases From Colorectal Cancer

Phase 1

Completed

Conditions: Colon Cancer
Rectal Cancer

Interventions: Drug: Floxuridine, Oxaliplatin, CPT-11

First Posted Date: 2008-06-11

Last Posted Date: 2021-07-01

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 52

Registration Number: NCT00695201

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Patients With Mouse Tyrp2 DNA: A Phase I Trial to Assess Safety and Immune Response

Phase 1

Completed

Conditions: Melanoma

Interventions: Biological: injection of mouse TYRP2 DNA

First Posted Date: 2008-05-20

Last Posted Date: 2011-03-28

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 12

Registration Number: NCT00680589

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Study Using High-Dose Single Fraction Image-Guided Radiotherapy for Metastatic Lesions to Soft Tissue Masses, Lymph Node, or Bone

Phase 1

Completed

Conditions: Metastatic Disease

Interventions: Radiation: intensity modulated radiation therapy

First Posted Date: 2008-05-15

Last Posted Date: 2015-11-17

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 68

Registration Number: NCT00678158

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients With Resected Stage I-III Non-small Cell Lung Cancer

Not Applicable

Completed

Conditions: Lung Cancer

Interventions: Drug: Bevacizumab (Avastin), Taxotere (Docetaxel), Vinorelbine Tartrate (Navelbine)

First Posted Date: 2008-05-09

Last Posted Date: 2015-11-20

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 25

Registration Number: NCT00675597

Locations: 🇺🇸
Memorial Sloan-Kettering at Mercy Medical Center, Rockville Centre, New York, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center @ Suffolk, Commack, New York, United States
🇺🇸
Memorial Sloan-Kettering at Basking Ridge, Basking Ridge, New Jersey, United States

and more 2 locations

Trial of Donor T Cells Sensitized With Pentadecapeptides of the CMV-PP65 Protein for the Treatment of Cytomegalovirus (CMV) Infections Following Allogeneic Hematopoietic Stem Cell Transplants

Phase 1

Completed

Conditions: Cytomegalovirus Infections

Interventions: Biological: CMV-Peptide-Specific T cells

First Posted Date: 2008-05-08

Last Posted Date: 2020-03-11

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 30

Registration Number: NCT00674648

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Lesion Dosimetry With 124-Iodine in Metastatic Thyroid Carcinoma

Phase 1

Active, not recruiting

Conditions: Thyroid Cancer

Interventions: Radiation: 131 I-iodine (131-I), 124 I-iodine (124-I)

First Posted Date: 2008-05-07

Last Posted Date: 2024-06-11

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 20

Registration Number: NCT00673010

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy